WAYNE, Pa.--(BUSINESS WIRE)--Jul 29, 2014--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical devices for critical care and surgery, has announced that its subsidiary Hotspur Technologies, Inc. received FDA 510(k) clearance to market the Arrow® GPSCath® Balloon Dilatation Catheters designed for use with .014” guide wires and in 150 cm length. These novel products enable a variety of peripheral vascular procedures to be performed below the knee with one dual function catheter, potentially reducing procedure time, radiation dosage, and expense for both patients and medical professionals.
The Arrow® GPSCath® Balloon Dilatation Catheter is the first dual functional balloon dilatation catheter that combines angioplasty with the proprietary VisioValve™ Injection System. This innovative combination enables physicians to perform peripheral below the knee angioplasty and inject physician selected fluids, such as contrast media, while maintaining guide wire position.
“With this latest product approval we continue our commitment to enabling medical professionals to perform peripheral access procedures that simplify and improve the doctor and patient experience while reducing health care costs,” said Benson Smith, Chairman, President & CEO of Teleflex. Added Smith, “We are excited to bring this innovative product for use in below the knee peripheral interventions to the market.” About Teleflex Incorporated Teleflex is a leading global provider of specialty medical devices for a range of procedures in critical care and surgery. Our mission is to provide solutions that enable healthcare providers to improve outcomes and enhance patient and provider safety. Headquartered in Wayne, PA, Teleflex employs approximately 11,400 people worldwide and serves healthcare providers in more than 150 countries. Additional information about Teleflex can be obtained from the company's website at teleflex.com.
Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.
Teleflex, GPSCath, Hotspur and VisioValve are trademarks or registered trademarks of Teleflex Incorporated or its affiliates. © 2014 Teleflex Incorporated. All rights reserved. MC-000259
CONTACT: Teleflex Incorporated Jake Elguicze Treasurer and Vice President, Investor Relations 610-948-2836 firstname.lastname@example.org www.teleflex.com KEYWORD: UNITED STATES NORTH AMERICA PENNSYLVANIA INDUSTRY KEYWORD: SURGERY HEALTH CARDIOLOGY MEDICAL DEVICES FDA SOURCE: Teleflex Incorporated Copyright Business Wire 2014 PUB: 07/29/2014 07:00 AM/DISC: 07/29/2014 07:00 AM http://www.businesswire.com/news/home/20140729005084/